StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$10.73−0.41 (-3.68%)

Close on Nov 18, 2026Market cap $1.25BP/E –Yield –

NovoCure revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

NovoCure's revenue for the twelve months ending Sep 30, 2026 was $725.39M, up 12.9% year over year. For fiscal 2025 it was $655.35M, up 8.3% from the year before. Over ten years it grew 34.8% a year on average. The highest annual figure on record is $655.35M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$655.35M+8.3%
FY2024Dec 31, 2024$605.22M+18.8%
FY2023Dec 31, 2023$509.34M-5.3%
FY2022Dec 31, 2022$537.84M+0.5%
FY2021Dec 31, 2021$535.03M+8.2%
FY2020Dec 31, 2020$494.37M+40.7%
FY2019Dec 31, 2019$351.32M+41.6%
FY2018Dec 31, 2018$248.07M+40.1%
FY2017Dec 31, 2017$177.03M+113.6%
FY2016Dec 31, 2016$82.89M+150.5%
FY2015Dec 31, 2015$33.09M+113.6%
FY2014Dec 31, 2014$15.49M+49.5%
FY2013Dec 31, 2013$10.36M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$193.40M+15.7%
Q2 FY2026Jun 30, 2026$183.58M+15.6%
Q1 FY2026Mar 31, 2026$174.06M+12.3%
Q4 FY2025Dec 31, 2025$174.35M+8.1%
Q3 FY2025Sep 30, 2025$167.20M+7.8%
Q2 FY2025Jun 30, 2025$158.81M+5.6%
Q1 FY2025Mar 31, 2025$154.99M+11.9%
Q4 FY2024Dec 31, 2024$161.27M+20.5%
Q3 FY2024Sep 30, 2024$155.10M+21.8%
Q2 FY2024Jun 30, 2024$150.36M+19.3%
Q1 FY2024Mar 31, 2024$138.50M+13.4%
Q4 FY2023Dec 31, 2023$133.78M+4.2%
Q3 FY2023Sep 30, 2023$127.32M-2.8%
Q2 FY2023Jun 30, 2023$126.05M-10.5%
Q1 FY2023Mar 31, 2023$122.18M-11.2%
Q4 FY2022Dec 31, 2022$128.43M-3.6%
Q3 FY2022Sep 30, 2022$131.00M-2.0%
Q2 FY2022Jun 30, 2022$140.87M+5.5%
Q1 FY2022Mar 31, 2022$137.55M+2.1%
Q4 FY2021Dec 31, 2021$133.21M-7.5%
Q3 FY2021Sep 30, 2021$133.61M+0.7%
Q2 FY2021Jun 30, 2021$133.52M+15.2%
Q1 FY2021Mar 31, 2021$134.70M+32.3%
Q4 FY2020Dec 31, 2020$143.95M+45.1%
Q3 FY2020Sep 30, 2020$132.66M+44.1%
Q2 FY2020Jun 30, 2020$115.93M+33.7%
Q1 FY2020Mar 31, 2020$101.83M+38.9%
Q4 FY2019Dec 31, 2019$99.23M+42.4%
Q3 FY2019Sep 30, 2019$92.06M+42.2%
Q2 FY2019Jun 30, 2019$86.71M+41.0%
Q1 FY2019Mar 31, 2019$73.31M+40.6%
Q4 FY2018Dec 31, 2018$69.67M+29.8%
Q3 FY2018Sep 30, 2018$64.76M+29.2%
Q2 FY2018Jun 30, 2018$61.51M+60.3%
Q1 FY2018Mar 31, 2018$52.13M+49.4%
Q4 FY2017Dec 31, 2017$53.66M+77.4%
Q3 FY2017Sep 30, 2017$50.11M–
Q2 FY2017Jun 30, 2017$38.38M–
Q1 FY2017Mar 31, 2017$34.88M–
Q4 FY2016Dec 31, 2016$30.24M–

More NovoCure figures

See a number that looks wrong?